First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients

First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients

Introduction.In the early 2000s, in type 2 diabetes mellitus (T2DM) treatment, a fundamentally new class of drugs appeared—the incretin mimetics. The use of dipeptidyl peptidase-4 (DPP-4) inhibitors allowed the safety of the T2DM therapy to be increased by reducing several parameters, including hypo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Karina Oganesovna Galstyan, Liudmila Viktorovna Nedosugova, Nina Alexandrovna Petunina, Julia Alexandrovna Trakhtenberg, Natalia Vadimovna Vostokova, Oksana Vladimirovna Karavaeva, Tatiana Evgenievna Chasovskaya
Formato: article
Lenguaje:EN
RU
Publicado: Endocrinology Research Centre 2016
Materias:
diabetes mellitus type 2
glycated hemoglobin
нbа1с
dpp-4 inhibitor
gosogliptin
vildagliptin
Nutritional diseases. Deficiency diseases
RC620-627
Acceso en línea:https://doaj.org/article/5f62c58ac7554d608a2ddc46a781c7e3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/5f62c58ac7554d608a2ddc46a781c7e3

Ejemplares similares